Company: PRTA
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001193125-25-174061
Chunk: 0

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-08-06
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

On August 6, 2025, Prothena Corporation plc (the “ Company”) issued a press release announcing that the Company’s partner Novo Nordisk announced its decision to advance coramitug into Phase 3 development for ATTR amyloidosis with cardiomyopathy. A copy of that press release is attached as Exhibit 99.1 to this Current Report on Form8-Kand is incorporated herein by reference.